STOCK TITAN

[Form 4] CHEMED CORP Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Chemed Corp (CHE) reported an insider equity award on Form 4. Joel L. Wherley, CEO of VITAS Healthcare, received a stock option grant covering 17,476 shares at an exercise price of $443.79 on 10/21/2025.

The options vest in three equal annual installments commencing 10/21/2026 and expire on 10/21/2030. Following the transaction, Wherley beneficially owned 32,819 derivative securities directly. No non-derivative share transactions were reported in Table I.

Chemed Corp (CHE) ha riportato un premio azionario da insider sul Form 4. Joel L. Wherley, CEO di VITAS Healthcare, ha ricevuto un grant di opzioni su azioni che copre 17,476 azioni a un prezzo di esercizio di $443.79 il 21/10/2025.

Le opzioni vestono in tre rate annuali uguali a partire dal 21/10/2026 e scadono il 21/10/2030. Dopo la transazione, Wherley possedeva direttamente 32,819 strumenti derivati. Nessuna operazione su azioni non derivate è stata riportata nella Tabella I.

Chemed Corp (CHE) reportó una adjudicación de acciones de insider en el Formulario 4. Joel L. Wherley, CEO de VITAS Healthcare, recibió una asignación de opciones sobre acciones que cubre 17,476 acciones a un precio de ejercicio de $443.79 el 21/10/2025.

Las opciones se consolidan/vesting en tres cuotas anuales iguales que comienzan el 21/10/2026 y expiran el 21/10/2030.

Tras la transacción, Wherley poseía directamente 32,819 valores derivados de forma beneficiosa. No se reportaron operaciones con acciones no derivadas en la Tabla I.

Chemed Corp (CHE)는 Form 4에 내부자에 의한 자본 배당을 보고했습니다. VITAS Healthcare의 CEO인 Joel L. Wherley가 17,476 주를 커버하는 주식매수선택권을 $443.79의 행사 가격으로 2025-10-21에 받았습니다.

옵션은 2026-10-21부터 시작해 세 차례의 동일한 연간 할부로 vest되며 2030-10-21에 만료됩니다.

거래 후 Wherley는 직접적으로 32,819개의 파생증권을 유리하게 보유했습니다. 표 I에 비파생 주식 거래는 보고되지 않았습니다.

Chemed Corp (CHE) a annoncé une attribution d'actions d'initié sur le formulaire 4. Joel L. Wherley, PDG de VITAS Healthcare, a reçu une attribution d'options d'achat couvrant 17 476 actions à un prix d'exercice de $443,79 le 21/10/2025.

Les options se vestent en trois tranches annuelles égales à partir du 21/10/2026 et expirent le 21/10/2030.

Suite à la transaction, Wherley détenait directement 32 819 titres dérivés de manière bénéficiaire. Aucune transaction sur des actions non dérivées n'a été signalée dans le tableau I.

Chemed Corp (CHE) meldete eine Insider-Eigenkapitalzuteilung auf Formular 4. Joel L. Wherley, CEO von VITAS Healthcare, erhielt eine Aktienoptionszuteilung über 17.476 Aktien zu einem Ausübungspreis von $443,79 am 21.10.2025.

Die Optionen vesten in drei gleichen jährlichen Raten, beginnend am 21.10.2026, und verfallen am 21.10.2030.

Nach der Transaktion hielt Wherley direkt 32.819 derivative Wertpapiere vorteilhaft. In Tabelle I wurden keine Transaktionen mit nicht-derivativen Aktien gemeldet.

قدمت Chemed Corp (CHE) مكافأة أسهم داخلية في النموذج 4. تلقّى جويل ل. ويرلي، الرئيس التنفيذي لـ VITAS Healthcare، منحة خيارات أسهم تغطي 17,476 سهماً بسعر تنفيذ $443.79 في 21/10/2025.

تتحقق/تكتسب الخيارات على ثلاث دفعات سنوية متساوية ابتداءً من 21/10/2026 وتنتهي في 21/10/2030.

بعد المعاملة، امتلك ويرلي فوائدياً مباشرةً 32,819 ورقة مالية مشتقة. لم تُذكر أي معاملات أسهم غير مشتقة في الجدول I.

Positive
  • None.
Negative
  • None.

Chemed Corp (CHE) ha riportato un premio azionario da insider sul Form 4. Joel L. Wherley, CEO di VITAS Healthcare, ha ricevuto un grant di opzioni su azioni che copre 17,476 azioni a un prezzo di esercizio di $443.79 il 21/10/2025.

Le opzioni vestono in tre rate annuali uguali a partire dal 21/10/2026 e scadono il 21/10/2030. Dopo la transazione, Wherley possedeva direttamente 32,819 strumenti derivati. Nessuna operazione su azioni non derivate è stata riportata nella Tabella I.

Chemed Corp (CHE) reportó una adjudicación de acciones de insider en el Formulario 4. Joel L. Wherley, CEO de VITAS Healthcare, recibió una asignación de opciones sobre acciones que cubre 17,476 acciones a un precio de ejercicio de $443.79 el 21/10/2025.

Las opciones se consolidan/vesting en tres cuotas anuales iguales que comienzan el 21/10/2026 y expiran el 21/10/2030.

Tras la transacción, Wherley poseía directamente 32,819 valores derivados de forma beneficiosa. No se reportaron operaciones con acciones no derivadas en la Tabla I.

Chemed Corp (CHE)는 Form 4에 내부자에 의한 자본 배당을 보고했습니다. VITAS Healthcare의 CEO인 Joel L. Wherley가 17,476 주를 커버하는 주식매수선택권을 $443.79의 행사 가격으로 2025-10-21에 받았습니다.

옵션은 2026-10-21부터 시작해 세 차례의 동일한 연간 할부로 vest되며 2030-10-21에 만료됩니다.

거래 후 Wherley는 직접적으로 32,819개의 파생증권을 유리하게 보유했습니다. 표 I에 비파생 주식 거래는 보고되지 않았습니다.

Chemed Corp (CHE) a annoncé une attribution d'actions d'initié sur le formulaire 4. Joel L. Wherley, PDG de VITAS Healthcare, a reçu une attribution d'options d'achat couvrant 17 476 actions à un prix d'exercice de $443,79 le 21/10/2025.

Les options se vestent en trois tranches annuelles égales à partir du 21/10/2026 et expirent le 21/10/2030.

Suite à la transaction, Wherley détenait directement 32 819 titres dérivés de manière bénéficiaire. Aucune transaction sur des actions non dérivées n'a été signalée dans le tableau I.

Chemed Corp (CHE) meldete eine Insider-Eigenkapitalzuteilung auf Formular 4. Joel L. Wherley, CEO von VITAS Healthcare, erhielt eine Aktienoptionszuteilung über 17.476 Aktien zu einem Ausübungspreis von $443,79 am 21.10.2025.

Die Optionen vesten in drei gleichen jährlichen Raten, beginnend am 21.10.2026, und verfallen am 21.10.2030.

Nach der Transaktion hielt Wherley direkt 32.819 derivative Wertpapiere vorteilhaft. In Tabelle I wurden keine Transaktionen mit nicht-derivativen Aktien gemeldet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Wherley Joel L

(Last) (First) (Middle)
255 EAST FIFTH STREET
SUITE 2600

(Street)
CINCINNATI OH 45202

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CHEMED CORP [ CHE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CEO - Vitas Healthcare
3. Date of Earliest Transaction (Month/Day/Year)
10/21/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy with tandem tax withholding) $443.79 10/21/2025 A 17,476 (1) 10/21/2030 Capital Stock 17,476 $443.79 32,819 D
Explanation of Responses:
1. Vesting in three equal annual installments commencing 10/21/2026
Joel L. Wherley 10/22/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Chemed Corp

NYSE:CHE

CHE Rankings

CHE Latest News

CHE Latest SEC Filings

CHE Stock Data

6.34B
14.29M
1.98%
97.98%
2.82%
Medical Care Facilities
Services-home Health Care Services
Link
United States
CINCINNATI